Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1 study found for:    NCT00001337
Show Display Options
Rank Status Study
1 Recruiting Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma (DLBCL);   Primary Mediastinal Large B-cell Lymphoma;   Burkitt Lymphoma;   Anaplastic Large-Cell Lymphoma;   Gray Zone Lymphoma
Interventions: Drug: EPOCH;   Biological: Rituximab

Study has passed its completion date and status has not been verified in more than two years.